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Abstract 
Objective: This study describes a restriction fragment polymorphism protocol for rapidly screening the polymor-
phism SLCO1B1 c.1929A>C in genomic DNA samples. The polymorphism SLCO1B1 c.1929A>C has been associated with 
increased activity resulting in increased hepatic uptake of drugs. Currently SLCO1B1 c.1929A>C is genotyped using 
direct sequencing techniques and 5′ nuclease based assays which can be cost prohibiting in resource limited settings. 
The aim of this study therefore was to design and validate a cost effective RFLP for genotyping the SLCO1B1 c.1929A>C 
polymorphism. This study was designed to investigate the effect of the polymorphism SLCO1B1 c.1929A>C on interin-
dividual variability in rosuvastatin pharmacokinetics in healthy volunteers of African descent.
Results: We describe a restriction fragment length polymorphism method to genotype SLCO1B1 c.1929A>C poly-
morphism using the restriction enzyme Ase1. A student’s t test with Welch correction was used to establish asso-
ciation between the SLCO1B1 c.1929A>C variant and rosuvastatin exposure. The frequency of the SLCO1B1 c.1929C 
allele amongst Zimbabweans was 6%. The SLCO1B1 c.1929C allele was associated with a 75% reduction (P < 0.001) in 
rosuvastatin exposure when compared to individuals carrying the wild type SLCO1B1 c.1929A allele. Polymorphism 
c.1929A>C may therefore play a significant role in rosuvastatin response. The RFLP method is quick and cost effective.
Keywords: SLCO1B1, Rosuvastatin, African, rs34671512, RFLP, Pharmacogenetics, Pharmacokinetics, SLCO1B1*22, 
SLCO1B1*35
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
As part of a larger pharmacogenetics study, we opted to 
explore the possible impact of single nucleotide poly-
morphism c.1929A>C; within the gene Solute carrier 
organic anion transporter family member 1B1 (SLCO1B1) 
on rosuvastatin pharmacokinetics. The SLCO1B1 
(c.1929A>C, p.Leu643Phe) SNP has been associated with 
altered OATP1B1 transporter activity [1]. The c.1929C 
allele has been associated with increased hepatic uptake 
of the antifolate methotrexate (P = 0.028) in cancer 
patients [2] and increased uptake of atorvastatin [3]. To 
do this we required a quick and cheap method to detect 
SLCO1B1 c.1929A>C in our study population. Currently, 
genotyping of the SLCO1B1 c.1929A>C is done using 
the relatively more expensive methods such as Sanger 
sequencing, 5′-nuclease assays [3], microarrays [2, 3]. 
Although methods such as mass arrays and sequencing 
offer more robust, automated and at times pre-validated 
options, restriction fragment length polymorphism 
(RFLP) remains an attractive method of choice for 
resource limited settings [4]. We describe, therefore, 
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Both forward and reverse PCR primers were designed 
using the PrimerQuest Tool (Integrated DNA Technol-
ogy, Iowa, USA) and tested for specificity using the NCBI 
Nucleotide Blast tool. The forward primer was 5′-GGC 
CAG AGG CAA CTA GAG TAT-3′ and 5′-ATA CTC TAG 
TTG CCT CTG GCC -3′ served as the reverse primer. 
Using the web based program NebCutter [5]; we selected 
the restriction enzyme Ase1 for the production of restric-
tion fragments.
Evaluation of the RFLP
To evaluate the RFLP we selected 157 genomic DNA 
samples from an in-house DNA bank wholly owned by 
the Pharmacogenomics and Cancer Research Group, in 
the Human Genetics Division, Faculty of Health Sciences 
at the University of Cape Town. All DNA samples have 
approval for use in ongoing pharmacogenomics research. 
All 157 DNA samples were obtained from Zimbabwean 
adults of self-reported African-Bantu descent. Ethnicity 
could be traced to the third generation.
Amongst these 157 individuals were 30 who took part 
in a pharmacokinetic study of rosuvastatin. Recruit-
ment of healthy volunteers for the rosuvastatin study 
has been reported elsewhere [6], briefly 30 healthy adult 
male (age 18–30  years) volunteers were recruited from 
the Harare Metropolitan Province, in Zimbabwe. Ethi-
cal approval for the pharmacokinetic trial was obtained 
from the Medicines Research Council of Zimbabwe (Ref: 
MRCZ/A/1793), The University of Cape Town Faculty 
of Health Sciences Research Ethics Committee (Ref: 
197/2014) and the Chitungwiza General Hospital Institu-
tion Review Board. After a 12 h overnight fast, each par-
ticipant administered 20 mg of rosuvastatin calcium with 
450  ml of water. Venous blood was collected over 30  h 
post drug administration and drug levels from each time 
point were estimated and the resultant drug concentra-
tions used to develop pharmacokinetic profiles of each 
individual. Rosuvastatin plasma concentrations were 
analysed using ultra performance liquid chromatography 
(UPLC) with mass spectrometric detection according to 
a method developed and validated by Astra Zeneca (Swe-
den) with a limit of detection of quantification for rosuv-
astatin in plasma was 0.47 ng/ml.
Genomic DNA was extracted from 1.5  ml of whole 
blood drawn from each participant using the QIAmp 
DNA Blood Kit (Qiagen, Hilden, Germany). The PCR 
proceeded as follows: each 25 µl reaction contained 75 ng 
of genomic DNA, 0.2× GoTaq PCR Buffer (Promega, 
Wisconsin, USA), 0.2 mM dNTPs (ThermoFisher Scien-
tific, Massachusetts, USA), 1.0 µM of each primer (Inte-
grated DNA Technology, Iowa, USA), 0.5  U of GoTaq 
(Promega, Wisconsin, USA), made up to 25  µl using 
nuclease free water. The reaction began with an initial 
denaturation at 94 °C for 5 min, followed by 40 cycles of 
denaturation at 94  °C for 45  s, annealing at 61.0  °C for 
30 s, extension at 72 °C for 1 min and a final extension at 
72 °C for 5 min. The PCR product was 470 bp in length.
The 470 bp amplicon was digested with Ase1 restriction 
enzyme (New England BioLabs, Massachusetts, USA) in 
a 30 µl digestion reaction consisting of 10 µl of the PCR 
product, 5 µl of NEB 3.1 10× Buffer (New England Bio-
Labs, Massachusetts, USA), 10U Ase1, the reaction was 
made up to 30 µl with nuclease free water. Digestion pro-
ceeded at 37 °C for an hour. Wild type SLCO1B1 c.1929A 
yielded two fragments 282 and 188 bp (Fig. 1), the restric-
tion site was abolished in the SLCO1B1 c.1929C variant 
yielded an undigested 470 bp fragment, whereas, the het-
erozygote SLCO1B1 c.1929A/C genotype yielded 3 frag-
ments of 470, 282 and 188 bp. Digested fragments were 
identified using gel electrophoresis on a 3% Invitrogen 
UltraPure Agarose gel (ThermoFisher Scientific, Massa-
chusetts, USA).
Validation of the RFLP method by Sanger sequencing
To validate the RFLP all sample amplicons were first 
cleaned in a 20 µl reaction that included 5 µl of the PCR 
product, 1U of FastAp thermosensitive alkaline phos-
phatase (ThermoScientific, UK), 2U Exonuclease 1 (Ther-
moScientific, UK), and incubated at 37  °C for 60  min 
followed by enzyme inactivation at 75 °C for 15 min using 
a MyCycler Thermal Cycler (Biorad, City, Country).
All cleaned amplicons were sequenced on an ABI 
3100 Gene Analyser (Applied Biosystems, Massachu-
setts, USA) using a Big Dye Terminator Cycle Sequenc-
ing Ready Kit (Applied Biosystems, Massachusetts, USA). 
For each of the sequencing reaction, one of the primers 
used for PCR amplification was used or both were used 
individually to confirm variations.
Data analysis
Sequencing data was analysed using SeqMan Pro 
(DNASTAR Inc., Madison, USA). All statistical analysis 
was done using Graph Pad Prism (Graph Pad Software 
Inc, California, USA). Chi square was used to check for 
adherence to Hardy–Weinberg Equilibrium; differences 
in allele frequencies were analysed using the non-par-
ametric One Way ANOVA (Kruskal Wallis test). Geno-
type associations with the phenotype peak serum drug 
concentration (Cmax), were analysed using the Student’s 
t test with Welch’s correction.
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Results and discussion
Allele and genotype frequencies are shown in Table 1. A 
total of 157 Zimbabwean samples were genotyped for the 
SLCO1B1 c.1929A>C SNP using both direct sequencing 
and the designed RFLP method. Comparison of results 
obtained using RFLP and direct sequencing showed 
a 100% correlation (see Fig.  1 showing an example of 
the comparison). All genotypes were consistent with 
Hardy–Weinberg equilibrium (P = 0.92). There were no 
statistically significant differences in the frequency of 
and SLCO1B1 c.1929C allele between the Zimbabwean 
population and all the major populations represented in 
the 1000 Genomes Project [7]. Amongst the 157 Zimba-
bwean samples genotyped, 30 individuals were healthy 
volunteers who participated in the rosuvastatin phar-
macokinetic trial. Of these 30 healthy individuals, three 
individuals had the SLCO1B1 c.1929C allele, these 3 indi-
viduals also carried the SLCO1B1 c.388G allele and there-
fore bore the SLCO1B1*35 haplotype. The SLCO1B1*35 
haplotype in this study population was 6%. None of 
the 157 individuals was homozygous for the SLCO1B1 
c.1929C allele, the genotype SLCO1B1 c.1929C/C is rare 
even amongst all the ethnic populations represented in 
the 1000 Genomes Database (Table 1).
Fig. 1 a Genotype validation by Sanger sequencing and b RFLP digest showing the AC genotype (digest yields 470, 282 and 188 bp fragments), 
the AA genotype (digest yields 282 and 188 bp) and undigested 470 bp controls
Table 1 Genotype distribution and  relative frequencies 
of  c.1929A>C in  30 healthy male Zimbabwean adults 
of Bantu ancestry
Population Allele frequency Genotype frequency
C A CC AA AC
This study 0.06 0.94 0.00 0.89 0.11
African 0.07 0.93 0.00 0.86 0.13
Caucasian 0.05 0.95 0.00 0.90 0.10
South Asian 0.05 0.95 0.00 0.90 0.10
East Asian 0.01 0.99 0.00 0.98 0.02
Fig. 2 Association of the c.1929A>C variant with the 
pharmacokinetics of rosuvastatin in 30 healthy male Zimbabwean 
adults of Bantu ancestry. Graph shows Cmax mean per genotype 
with SM in bracket
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The SLCO1B1 c.1929A/C genotype was associated 
with a 75% reduction in Cmax (P < 0.001) of rosuvastatin 
(Fig. 2) when compared to individuals with the SLCO1B1 
c.1929A/A genotype. This reduction in Cmax in carri-
ers of SLCO1B1 c.1929C allele could indicate a potential 
increase in hepatic uptake due to increased transporter 
activity. These results are consistent with the possible 
increased hepatic uptake by the OATP1B1  Phe643 vari-
ant reported previously for both methotrexate [2] and 
atorvastatin [3]. In addition, this study reports the pos-
sible importance of the SLCO1B1 c.1929A>C in interindi-
vidual response to rosuvastatin therapy. The liver serves 
as both the target of statin therapeutic activity and dis-
position therefore carriers of SLCO1B1 c.1929.C variant 
are likely to have larger positive outcomes than non-car-
riers and possibly reduced incidence of SIM. However, 
questions remain on the possible impact of SLCO1B1 
c.1929A>C on the pharmacotherapy of drugs like lopi-
navir and methotrexate, where increased hepatic uptake 
may potentially lower drug efficacy and therapeutic 
outputs.
Conclusions
The RFLP method we describe here is quick, accurate 
and cost effective, it may assist in increasing evaluation 
of this important variant in a concerted effort to improve 
efficacious and safe use of drugs whose transport is medi-
ated by the SLCO1B1 transporter OATP1B1.
Limitations
The major limitation of this study was the sample size. 
However, the RFLP described here can be used to gen-
otype larger sample sets as it is relatively cost effective 
when compared to current genotyping methods. In addi-
tion, the application of this RFLP in genotyping SLCO1B1 
c.1929A>C in participants of the rosuvastatin pharma-
cokinetics trial launches the need for further investiga-
tion of this polymorphism and its effect on OATP1B1 
transporter activity.
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